By Fineline Cube Becton, Dickinson and Co. (BD) and Swiss injection system developer Ypsomed announced an expanded collaboration to develop a 5.5mL version of the BD Neopak XtraFlow glass prefilled syringe, designed for full compatibility with Ypsomed’s YpsoMate 5.5 auto‑injector platform. The partnership aims to provide pharmaceutical companies and patients requiring high‑volume subcutaneous self‑injection with enhanced delivery options.
Collaboration Structure & Product Specifications
| Item | Detail |
|---|---|
| Companies | Becton, Dickinson and Co. (BD) / Ypsomed |
| Product | BD Neopak XtraFlow 5.5mL glass prefilled syringe |
| Platform Compatibility | YpsoMate 5.5 auto‑injector |
| Target Indication | High‑volume subcutaneous self‑injection therapies |
| Market Focus | Pharmaceutical companies and patients |
| Innovation | First 5.5mL Neopak XtraFlow syringe optimized for auto‑injector integration |
| Development Stage | Co‑development phase; regulatory filing preparation underway |
Technology Profile & Strategic Differentiation
- Neopak XtraFlow: BD’s advanced glass prefilled syringe platform featuring ultra‑low tungsten residual, reduced particle generation, and enhanced break resistance
- YpsoMate 5.5: Ypsomed’s next‑generation auto‑injector designed for larger‑volume biologics (up to 5.5mL), supporting patient‑friendly self‑administration
- Synergy: Combined solution addresses growing demand for high‑concentration, high‑volume biologics in immunology, oncology, and metabolic diseases
- Patient Benefit: Enables less frequent dosing and improved adherence for chronic conditions requiring large‑volume injections
Market Impact & Commercial Outlook
- Subcutaneous Biologics Market: Global market valued at $120 billion in 2025, with high‑volume formulations growing at 15% CAGR
- Competitive Advantage: Integrated BD‑Ypsomed solution reduces development risk for pharma clients by ensuring primary container and device compatibility from inception
- Revenue Potential: Analysts estimate the 5.5mL prefilled syringe market will exceed $2 billion by 2030, driven by biosimilar and novel biologic launches
- Strategic Fit: Expands BD’s leadership in prefilled systems while strengthening Ypsomed’s position in large‑volume auto‑injectors
- Launch Timeline: Commercial availability targeted for 2027, pending regulatory clearances
Forward‑Looking Statements
This brief includes forward‑looking statements regarding development timelines, market projections, and commercial launch expectations for the Neopak XtraFlow 5.5mL syringe. Actual results may differ due to technical challenges, regulatory review outcomes, and competitive dynamics in the drug delivery market.-Fineline Info & Tech